抗凝血酶
医学
心室辅助装置
凝血酶
部分凝血活酶时间
抗凝剂
凝血酶生成
血栓形成
重症监护医学
麻醉
肝素
心脏病学
外科
内科学
心力衰竭
凝结
血小板
作者
Liqin Ling,Chaonan Liu,Jing Zhou
出处
期刊:Labmedicine
[Oxford University Press]
日期:2025-03-14
卷期号:56 (4): 423-427
标识
DOI:10.1093/labmed/lmae113
摘要
Abstract Introduction Appropriate bridging anticoagulation is critical in the early postoperative period after left ventricular assist device (LVAD) implantation, because the patients are usually in a fragile balance of thrombotic to bleeding risk. Unfortunately, the ideal manner of monitoring postoperative bridging anticoagulation remains undetermined. Methods Here we reported a case demonstrating that thrombin-antithrombin complex might be an option in this situation. Results This patient suffered thrombosis and bleeding simultaneously within 7 days after implantation, and the 2 commonly used methods for monitoring bridging anticoagulation, activated partial thromboplastin time and anti-Xa activity, were incompatible with each other. After a multi-disciplinary team discussion, the clinicians decided to manage his anticoagulation based on thrombin-antithrombin complex level. It worked out well, and the patient was transferred to a general ward 2 weeks later. Discussion With respect to clinical endpoints, thrombin-antithrombin complex might be a promising parameter for monitoring anticoagulation in the early postoperative period after LVAD implantation.
科研通智能强力驱动
Strongly Powered by AbleSci AI